Solid Biosciences (NASDAQ:SLDB – Free Report) had its price objective reduced by Barclays from $18.00 to $15.00 in a report released on Wednesday, Benzinga reports. They currently have an overweight rating on the stock.
SLDB has been the topic of several other reports. HC Wainwright reiterated a buy rating and set a $16.00 target price on shares of Solid Biosciences in a report on Wednesday. JPMorgan Chase & Co. upgraded Solid Biosciences from a neutral rating to an overweight rating and boosted their price objective for the company from $10.00 to $15.00 in a research report on Monday, July 15th. Piper Sandler restated an overweight rating and set a $20.00 target price on shares of Solid Biosciences in a report on Friday, June 21st. SVB Leerink upgraded shares of Solid Biosciences from a market perform rating to an outperform rating and set a $12.00 price target for the company in a report on Monday, June 24th. Finally, Leerink Partnrs upgraded shares of Solid Biosciences from a hold rating to a strong-buy rating in a report on Monday, June 24th. Eight equities research analysts have rated the stock with a buy rating and one has given a strong buy rating to the stock. According to MarketBeat, the stock currently has a consensus rating of Buy and a consensus price target of $15.67.
Check Out Our Latest Stock Analysis on SLDB
Solid Biosciences Price Performance
Solid Biosciences (NASDAQ:SLDB – Get Free Report) last issued its earnings results on Tuesday, August 13th. The company reported ($0.61) EPS for the quarter, beating the consensus estimate of ($0.66) by $0.05. On average, equities analysts predict that Solid Biosciences will post -2.71 earnings per share for the current year.
Institutional Trading of Solid Biosciences
A number of institutional investors have recently made changes to their positions in SLDB. Algert Global LLC bought a new position in Solid Biosciences in the second quarter valued at $82,000. Susquehanna Fundamental Investments LLC acquired a new position in shares of Solid Biosciences during the 2nd quarter worth about $92,000. Millennium Management LLC grew its holdings in shares of Solid Biosciences by 135.7% in the 2nd quarter. Millennium Management LLC now owns 1,728,065 shares of the company’s stock valued at $9,798,000 after acquiring an additional 994,984 shares in the last quarter. Cubist Systematic Strategies LLC acquired a new stake in shares of Solid Biosciences in the second quarter valued at about $412,000. Finally, Point72 DIFC Ltd acquired a new stake in shares of Solid Biosciences in the second quarter valued at about $58,000. Institutional investors own 81.46% of the company’s stock.
Solid Biosciences Company Profile
Solid Biosciences Inc, a life science company, develops therapies for neuromuscular and cardiac diseases in the United States. The company's lead product candidate is SGT-003, a gene transfer candidate for the treatment of Duchenne muscular dystrophy; and SGT-501 to treat Catecholaminergic polymorphic ventricular tachycardia.
Further Reading
- Five stocks we like better than Solid Biosciences
- How to Invest in Biotech Stocks
- Bumble’s Valuation Hits an All-Time Low, Can Its Fortunes Change?
- Business Services Stocks Investing
- MarketBeat Week in Review – 8/12 – 8/16
- Best Stocks Under $10.00
- JD.com Earnings Surprise: China’s Outlook Better Than Expected
Receive News & Ratings for Solid Biosciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Solid Biosciences and related companies with MarketBeat.com's FREE daily email newsletter.